InVitae (NYSE:NVTA) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.
This is a summary of recent recommendations for InVitae and Personalis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
InVitae presently has a consensus target price of $26.50, suggesting a potential upside of 9.41%. Personalis has a consensus target price of $28.25, suggesting a potential upside of 26.00%. Given Personalis’ higher probable upside, analysts clearly believe Personalis is more favorable than InVitae.
This table compares InVitae and Personalis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares InVitae and Personalis’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|InVitae||$147.70 million||14.73||-$129.35 million||($1.94)||-12.48|
Personalis has lower revenue, but higher earnings than InVitae.
Institutional & Insider Ownership
78.9% of InVitae shares are owned by institutional investors. 5.7% of InVitae shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
InVitae beats Personalis on 5 of the 9 factors compared between the two stocks.
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.